Last reviewed · How we verify
NCT04759872
Insulin and Muscle Fat Metabolism
NA trial testing Hyperinsulinemic-euglycemic Clamp in Overweight and Obesity in 9 participants. Terminated before completion.
7 June 2022
Quick facts
| Lead sponsor | Oregon State University |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 9 |
| Start date | 22 February 2021 |
| Primary completion | 7 June 2022 |
| Estimated completion | 7 June 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hyperinsulinemic-euglycemic Clamp
Conditions studied
- Overweight and Obesity — all drugs for Overweight and Obesity →
- Insulin Resistance — all drugs for Insulin Resistance →
- Metabolic Disease — all drugs for Metabolic Disease →
- Mitochondrial Metabolism — all drugs for Mitochondrial Metabolism →
Sponsor
Oregon State University
Who can join
Adults 30 to 55, any sex, with Overweight and Obesity or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our objective in this study is to identify the extent to which insulin drives the accumulation of lipids in skeletal muscle of humans. We will test the hypothesis that 4-hours of mild hyperinsulinemia will result in significant muscle lipid accumulation and that such effects will be similar in lean and overweight/obese humans.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04759872
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight and Obesity
Currently open trials in the same condition.
- NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
- NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
- NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
Other Oregon State University trials
Trials by the same sponsor.
- NCT06384742 — Shift Worker Intervention for Sleep Health · NA · recruiting
- NCT05965609 — Optimizing Sleep Health in Nurses · NA · completed
- NCT05950672 — Development and Evaluation CAT and Youth · NA · completed
- NCT05482464 — Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irrita · NA · completed
- NCT06915129 — The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04759872 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon State University
- Last refreshed: 10 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04759872.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing